Jordan Kadish

News

Sorafenib Maintenance Post-Transplantation Among Patients With FLT3-ITD Mutated AML

04/15/2023

According to a phase 3 trial, sorafenib maintenance post-transplantation yielded safe results among patients with FLT3-ITD mutated AM undergoing allogeneic hematopoietic stem cell transplantation.

According to a phase 3 trial,...

04/15/2023

Oncology

News

Efficacy and Safety of Rituximab-Bendamustine vs R-CHOP Among Patients With Follicular Lymphoma

06/26/2023

Jordan Kadish ;

Rituximab-bendamustine and R-CHOP yielded similar efficacy results, but had distinct safety profiles and long-term events among patients with follicular lymphoma.

Rituximab-bendamustine and...

06/26/2023

Oncology

News

BET Inhibitor Trotabresib Demonstrated Antitumor Activity Among Patients With Heavily Pretreated R/R DLBCL

08/01/2023

Jordan Kadish ;

Oral BET inhibitor trotabresib showed antitumor activity profile among patients with heavily pretreated R/R diffuse large B-cell lymphoma or advanced solid tumors, demonstrating its potential value in combination with other anticancer agents.

Oral BET inhibitor trotabresib...

08/01/2023

Oncology

News

Brexucabtagene Autoleucel vs Standard-Of-Care Treatment for Patients With R/R MCL

11/28/2023

Jordan Kadish ;

According to a comparative analysis of the SCHOLAR-2 and ZUMA-2 trials, brexucabtagene autoleucel showed significant survival benefits compared to the standard-of-care treatment for patients with R/R mantle cell lymphoma after covalent BTK...

According to a comparative...

11/28/2023

Oncology

FDA Approval

FDA Approves Biweekly Dosing of Teclistamab for Patients With Relapsed/Refractory Multiple Myeloma

02/21/2024

Jordan Kadish ;

On February 20, 2024, the FDA granted approval for teclistamab administered with biweekly dosing for patients with relapsed/refractory multiple myeloma.

On February 20, 2024, the FDA...

02/21/2024

Oncology

News

Luxeptinib Demonstrates Positive Antitumor Activity in Patients With Relapsed/Refractory B-Cell Malignancies

02/15/2023

Jordan Kadish ;

A phase 1a/b study found that luxeptinib resulted in positive antitumor activity post-ibrutinib relapse and did not lead to greater pharmacokinetics exposure in patients with R/R B-cell malignancies.

A phase 1a/b study found that...

02/15/2023

Oncology

News

Ruxolitinib or Fedratinib Combined With BMS-986158 Yielded Robust Sustained Viral Response in Patients With Myelofibrosis

02/14/2023

Jordan Kadish ;

A phase 1/2 dose escalation study found that a combination of BMS-986158 and ruxolitinib or fedratinib for patients with intermediate to high-risk myelofibrosis resulted in robust SVR, with deepened responses following continued treatment.

A phase 1/2 dose escalation...

02/14/2023

Oncology

News

Oral Azacitidine Plus CHOP Demonstrates Safety, Efficacy for Patients With Peripheral T-Cell Lymphomas With T-Follicular Helper Phenotype

08/02/2023

Jordan Kadish ;

A phase 2 trial indicated that the combination of oral azacitidine plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) as initial treatment for patients with peripheral T-cell lymphomas with T-follicular helper phenotype...

A phase 2 trial indicated that...

08/02/2023

Oncology

News

Triplet Combination Yields Encouraging Activity for Newly Diagnosed Secondary AML, MDS, or CMML After Failure of Hypomethylating Agents

09/27/2023

Jordan Kadish ;

The combination of azacitidine, venetoclax, and pevonedistat yielded encouraging efficacy among a poor-risk population of patients with AML, MDS or CMML, according to a phase 1/2 trial.

The combination of azacitidine,...

09/27/2023

Oncology

News

Zanubrutinib Continues to Exhibit Sustained Responses and Tolerable Safety Among Patients With R/R MZL

01/19/2024

Jordan Kadish ;

Zanubrutinib continued to demonstrate sustained responses and tolerable safety among patients with R/R marginal zone lymphoma who had received at least 1 anti-CD20-directed regimen, according to the final analysis of the phase 2 MAGNOLIA...

Zanubrutinib continued to...

01/19/2024

Oncology